Bexmarilimab* in combination with azacitidine showed ORR of 100% and 89% in treatment-naïve and HMA-failed HR-MDS patients, respectively
Majority of treatment-emergent adverse events (TEAE) were mild to moderate, and only 6% were related to bexmarilimab
Treatment was well-tolerated, with no dose-limiting toxicities
Estimated median overall survival of 13.4 months in patients with HMA-failed MDS and 8.1 months in patients with r/r AML
Two HMA-failed MDS patients received a hematopoietic stem cell transplantation (HSCT) after treatment
Bone marrow immune biomarkers increased after treatment by nearly 3-fold versus baseline. An increase in biomarkers (HLA-DR molecules) seen in 67% of patients with HMA-failed MDS reinforces bexmarilimab’s mode of action.